{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:17:29Z","timestamp":1783095449464,"version":"3.54.6"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is little information on the pharmacokinetics and pharmacodynamics of sacubitril\/valsartan (SV) in patients undergoing peritoneal dialysis (PD) complicated with hypertension or heart failure (HF). This study was designed to evaluate the pharmacokinetics and pharmacodynamics of SV in PD patients with complications of hypertension or HF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was an open-label and cross-sectional study investigating PD patients diagnosed with hypertension or New York Heart Association Class II\u2013IV HF. The concentrations of valsartan, sacubitril and sacubitrilat (LBQ657) were measured by ultra-performance liquid chromatography tandem mass spectrometry in plasma, urine and peritoneal dialysate samples. Pharmacodynamics were evaluated by comparing changes in mean sitting systolic blood pressure (msSBP), mean sitting diastolic blood pressure (msDBP), mean sitting heart rate, N-terminal-pro B-type natriuretic peptide (NT-proBNP) and left ventricular ejection fraction (LVEF).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty patients with PD were enrolled including 27 (67.5%) patients with hypertension, 4 (10%) patients with HF and 9 (22.5%) patients with both hypertension and HF. This study included three treatment cohorts: 50\u00a0mg twice daily (BID), 100\u00a0mg once daily and 100\u00a0mg BID. The plasma maximum drug concentrations in the 100\u00a0mg BID group were 1995\u00a0\u00b1\u00a01499\u00a0ng\/mL for valsartan, 171\u00a0\u00b1\u00a0148\u00a0ng\/mL for sacubitril and 13\u00a0686\u00a0\u00b1\u00a07418\u00a0ng\/mL for LBQ657. The 24-h recovery rate of LBQ657 was 3.77% in urine and 2.23% in peritoneal dialysate. After taking SV, msSBP and msDBP decreased by 19.25\u00a0\u00b1\u00a010.32\u00a0mmHg and 10.10\u00a0\u00b1\u00a08.00\u00a0mmHg from baseline, respectively. NT-proBNP decreased by 1436.50 (0.00\u201318\u00a0198.00) from baseline, while LVEF increased by 5.00 (\u20130.25 to 9.25) from baseline after SV treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PD and residual renal function contributed only to a minor degree to the elimination of LBQ657. Additionally, a dose of 100\u00a0mg BID SV is safe and effective in patients with PD with complications of hypertension or HF.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfad038","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:49:52Z","timestamp":1676422192000},"page":"1880-1889","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacokinetics and pharmacodynamics of sacubitril\/valsartan in peritoneal dialysis patients"],"prefix":"10.1093","volume":"38","author":[{"given":"Yi","family":"He","sequence":"first","affiliation":[{"name":"Kidney Research Institute, Department of Nephrology, West China Hospital of Sichuan University , Sichuan, Chengdu , China"},{"name":"Department of Nephrology, Yaan People's Hospital , Sichuan, Yaan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jin","sequence":"additional","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hen","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yaan People's Hospital , Sichuan, Yaan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhan","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxi","family":"Liao","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Department of Nephrology, West China Hospital of Sichuan University , Sichuan, Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoli","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yaan People's Hospital , Sichuan, Yaan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Zhou","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Department of Nephrology, West China Hospital of Sichuan University , Sichuan, Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"He","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Department of Nephrology, West China Hospital of Sichuan University , Sichuan, Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Qin","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Department of Nephrology, West China Hospital of Sichuan University , Sichuan, Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo","family":"Li","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Department of Nephrology, West China Hospital of Sichuan University , Sichuan, Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqun","family":"Zou","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Department of Nephrology, West China Hospital of Sichuan University , Sichuan, Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gan","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Department of Nephrology, West China Hospital of Sichuan University , Sichuan, Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlei","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-4824","authenticated-orcid":false,"given":"Li","family":"Zheng","sequence":"additional","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhong","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Department of Nephrology, West China Hospital of Sichuan University , Sichuan, Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fu","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Department of Nephrology, West China Hospital of Sichuan University , Sichuan, Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"2023073100371909200_bib1","doi-asserted-by":"crossref","first-page":"38768","DOI":"10.1038\/srep38768","article-title":"A nationwide cross-sectional survey on prevalence, management and pharmacoepidemiology patterns on hypertension in Chinese patients with chronic kidney disease","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"2023073100371909200_bib2","first-page":"827","article-title":"A cross-sectional investigation of hypertension in patients with chronic kidney disease","author":"Jing","year":"2009","journal-title":"Chin J Nephrol"},{"key":"2023073100371909200_bib3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jash.2011.02.004","article-title":"Hypertension in peritoneal dialysis patients: epidemiology, pathogenesis, and treatment","volume":"5","author":"Ortega","year":"2011","journal-title":"J Am Soc Hypertens"},{"key":"2023073100371909200_bib4","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/ndt\/14.6.1536","article-title":"Prevalence of hypertension in patients on peritoneal dialysis: results of an Italian multicentre study","volume":"14","author":"Cocchi","year":"1999","journal-title":"Nephrol Dialysis Transplant"},{"key":"2023073100371909200_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/089686080902900210","article-title":"Association between pulse pressure and mortality in patients undergoing peritoneal dialysis","volume":"29","author":"Fang","year":"2009","journal-title":"Perit Dial Int"},{"key":"2023073100371909200_bib6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2215\/CJN.07130810","article-title":"Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis","volume":"6","author":"Wang","year":"2011","journal-title":"Clin J Soc Nephrol"},{"key":"2023073100371909200_bib7","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2019.01.001","article-title":"US Renal Data System 2018 Annual Data Report: epidemiology of kidney disease in the United States","volume":"73","author":"Saran","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2023073100371909200_bib8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","article-title":"Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study","volume":"63","author":"Kario","year":"2014","journal-title":"Hypertension"},{"key":"2023073100371909200_bib9","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"2023073100371909200_bib10","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur Heart J"},{"key":"2023073100371909200_bib11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2023073100371909200_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40262-017-0558-9","article-title":"Erratum to: Clinical pharmacokinetics of sacubitril\/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor","volume":"57","author":"Ayalasomayajula","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2023073100371909200_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2023073100371909200_bib14","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehv142","article-title":"Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials","volume":"36","author":"Bavishi","year":"2015","journal-title":"Eur Heart J"},{"key":"2023073100371909200_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/hr.2015.1","article-title":"Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction","volume":"38","author":"Ito","year":"2015","journal-title":"Hypertens Res"},{"key":"2023073100371909200_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/phar.2075","article-title":"PARADIGM-HF trial: secondary analyses address unanswered questions","volume":"38","author":"Smith","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2023073100371909200_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/0896860820982218","article-title":"ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults: classification, measurement, interpretation and rationale for intervention","volume":"41","author":"Morelle","year":"2021","journal-title":"Perit Dial Int"},{"key":"2023073100371909200_bib18","doi-asserted-by":"crossref","first-page":"123402","DOI":"10.1016\/j.jchromb.2022.123402","article-title":"Simultaneous determination and pharmacokinetics study of valsartan, sacubitril and its major metabolite in human plasma, urine and peritoneal dialysis fluid in patients with end-stage renal disease by UPLC\u2013MS\/MS","volume":"1208","author":"Ying","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2023073100371909200_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","article-title":"Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV","volume":"18","author":"Williams","year":"2004","journal-title":"J Hum Hypertens"},{"key":"2023073100371909200_bib20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","article-title":"Pharmacokinetics and dosage adjustment in patients with renal dysfunction","volume":"65","author":"Verbeeck","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"2023073100371909200_bib21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1124\/dmd.104.000521","article-title":"Effects of uremic toxins on hepatic uptake and metabolism of erythromycin","volume":"32","author":"Sun","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"2023073100371909200_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1254\/jphs.08042FP","article-title":"Effect of hemodialysis on hepatic cytochrome P450 functional expression","volume":"108","author":"Michaud","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"2023073100371909200_bib23","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2215\/CJN.01580407","article-title":"Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin","volume":"2","author":"How","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023073100371909200_bib24","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3109\/00498254.2015.1014944","article-title":"Disposition and metabolism of [(14)C] sacubitril\/valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects","volume":"46","author":"Flarakos","year":"2016","journal-title":"Xenobiotica"},{"key":"2023073100371909200_bib25","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00228-016-2072-7","article-title":"Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril\/valsartan), an angiotensin receptor neprilysin inhibitor","volume":"72","author":"Ayalasomayajula","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"2023073100371909200_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000336933","article-title":"Appropriate drug dosing in patients receiving peritoneal dialysis","volume":"177","author":"Hirata","year":"2012","journal-title":"Contrib Nephrol"},{"key":"2023073100371909200_bib27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000519643","article-title":"Pharmacokinetics and pharmacodynamics of sacubitril\/valsartan in maintenance hemodialysis patients with heart failure","volume":"51","author":"Feng","year":"2022","journal-title":"Blood Purif"},{"key":"2023073100371909200_bib28","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"2023073100371909200_bib29","doi-asserted-by":"crossref","first-page":"657067","DOI":"10.3389\/fmed.2021.657067","article-title":"Effects of sacubitril-valsartan in heart failure with preserved ejection fraction in patients undergoing peritoneal dialysis","volume":"8","author":"Fu","year":"2021","journal-title":"Front Med"},{"key":"2023073100371909200_bib30","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ehf2.12659","article-title":"Sacubitril\/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease","volume":"7","author":"Lee","year":"2020","journal-title":"ESC Heart Failure"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad038\/50105606\/gfad038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/8\/1880\/50956410\/gfad038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/8\/1880\/50956410\/gfad038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:37:45Z","timestamp":1690763865000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/8\/1880\/7036797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,2,14]]},"published-print":{"date-parts":[[2023,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad038","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,2,14]]}}}